{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:26:07Z","timestamp":1788312367141,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014538","name":"Lembaga Pengelola Dana Pendidikan","doi-asserted-by":"publisher","award":["00169\/BPPT\/BPI.06\/9\/2023"],"award-info":[{"award-number":["00169\/BPPT\/BPI.06\/9\/2023"]}],"id":[{"id":"10.13039\/501100014538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated efficacy in glycaemic control and cardiorenal protection across multiple meta-analyses. However, their applicability to the Indonesian population remains uncertain due to demographic, lifestyle, and healthcare disparities. This study aims to evaluate the effectiveness of SGLT2is in managing metabolic control, cardiorenal risk factors, and their safety relative to non-SGLT2is in the T2DM population in Indonesian real clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study applied a multicenter retrospective cohort design, enrolling adult Indonesian T2DM patients who had received treatment for at least 12 months. Intragroup paired analysis and intergroup comparative studies were performed regarding metabolic control, cardiorenal, and safety parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 638 patients were included, with 319 patients contributing to paired analyses. In paired data analysis, SGLT2is significantly improved HbA1c, fasting plasma glucose (FPG), body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid profile, and atherosclerotic cardiovascular disease (ASCVD) risk (p\u2009&lt;\u20090.05). Compared to non-SGLT2is, SGLT2is are associated with greater reductions in HbA1c, FPG, body weight, BMI, and SBP. Although no intergroup differences were observed in other parameters, adjusted analyses revealed additional benefits of SGLT2is in lowering low-density lipoprotein (LDL) cholesterol and maintaining estimated Glomerular Filtration Rate (eGFR), though SBP effects became nonsignificant. No major safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings support the use of SGLT2is as effective agents for improving glycaemic control, body weight, blood pressure, lipid profile, and ASCVD risk in Indonesian patients with T2DM. Further studies are warranted to clarify their safety, long-term renal effects, and to explore the comparative effects of individual SGLT2is and dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0353564","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:24:04Z","timestamp":1784309044000},"page":"e0353564","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-1402","authenticated-orcid":true,"given":"Fonny","family":"Cokro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7861-4369","authenticated-orcid":true,"given":"Rani","family":"Sauriasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicky Levenus","family":"Tahapary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heri","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tricaesario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul","family":"Hidayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Djauhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5609-2413","authenticated-orcid":true,"given":"Jimmy","family":"Tandradynata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidartawan","family":"Soegondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"pone.0353564.ref001","unstructured":"International Diabetes Federation, Resources, diabetes L with, Acknowledgement, FAQs, Contact, et al. IDF Diabetes Atlas 2021 | IDF Diabetes Atlas [Internet]. [cited 2022 Oct 7]. Available from: https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/"},{"issue":"7","key":"pone.0353564.ref002","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"SM Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"10225","key":"pone.0353564.ref003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"B Bikbov","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"pone.0353564.ref004","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"BL Neuen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"pone.0353564.ref005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.29090\/psa.2024.04.24.AP0606","article-title":"Effects of SGLT2 inhibitors compared with sulfonylurea on glycaemic control and cardiovascular risk reduction in Asia: meta-analysis","volume":"51","author":"F Cokro","year":"2024","journal-title":"Pharm Sci Asia"},{"issue":"12","key":"pone.0353564.ref006","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE Trial","volume":"15","author":"G Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0353564.ref007","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1472-6823-13-58","article-title":"Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials","volume":"13","author":"A Berhan","year":"2013","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"pone.0353564.ref008","doi-asserted-by":"crossref","DOI":"10.52225\/narra.v5i1.2089","article-title":"Analysis of specialist doctors\u2019 behavior towards SGLT2 inhibitors prescription in Indonesia: a qualitative study","volume":"5","author":"F Cokro","year":"2025","journal-title":"Narra J"},{"issue":"11","key":"pone.0353564.ref009","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.3390\/ijms22115808","article-title":"Gender differences in diabetic kidney disease: focus on hormonal, genetic and clinical factors","volume":"22","author":"A Giandalia","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0353564.ref010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diabres.2017.08.013","article-title":"Longitudinal trends in HbA1c and associations with comorbidity and all-cause mortality in Asian patients with type 2 diabetes: a cohort study","volume":"133","author":"M Luo","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"pone.0353564.ref011","doi-asserted-by":"crossref","first-page":"133079","DOI":"10.1016\/j.ijcard.2025.133079","article-title":"Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis","volume":"426","author":"R Kani","year":"2025","journal-title":"Int J Cardiol"},{"issue":"1","key":"pone.0353564.ref012","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"F Shigiyama","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"pone.0353564.ref013","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11255-019-02112-6","article-title":"Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"51","author":"C Feng","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"pone.0353564.ref014","first-page":"100742","article-title":"Validation of the general Framingham Risk Score (FRS), SCORE2, revised PCE and WHO CVD risk scores in an Asian population","volume":"35","author":"SS Kasim","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"pone.0353564.ref015","unstructured":"AstraZeneca Canada, Inc. Product Monograph Including Patient Medication Information: Forxiga\u00ae [Internet]. 2023. Available from: https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/forxiga-product-monograph-en.pdf"},{"issue":"5","key":"pone.0353564.ref016","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000447936","article-title":"Risk factors and prognosis of cardiorenal syndrome type 1 in elderly Chinese patients: a retrospective observational cohort study","volume":"41","author":"W Hu","year":"2016","journal-title":"Kidney Blood Press Res"},{"key":"pone.0353564.ref017","article-title":"Factors associated with cardiorenal syndrome in patients with decompensated heart failure","volume":"34","author":"LM Zhao","year":"2021","journal-title":"Acta Paul Enferm"},{"issue":"2","key":"pone.0353564.ref018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/clinchem\/hvad190","article-title":"The Sampson-NIH equation is the preferred calculation method for LDL-C","volume":"70","author":"M Sampson","year":"2024","journal-title":"Clin Chem"},{"key":"pone.0353564.ref019","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"issue":"7258","key":"pone.0353564.ref020","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"S Im","year":"2000","journal-title":"BMJ"},{"issue":"3","key":"pone.0353564.ref021","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1463-1326.2009.01155.x","article-title":"Benefits of moderate weight loss in patients with type 2 diabetes","volume":"12","author":"K Fujioka","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"pone.0353564.ref022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2840-13-65","article-title":"Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study","volume":"13","author":"K Kaku","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"pone.0353564.ref023","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Z Szekeres","year":"2021","journal-title":"Metabolites"},{"issue":"17","key":"pone.0353564.ref024","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Y Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"pone.0353564.ref025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41598-020-80603-8","article-title":"Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"D Gebrie","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0353564.ref026","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diabet.2020.01.002","article-title":"Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials","volume":"46","author":"AJ Scheen","year":"2020","journal-title":"Diabetes Metab"},{"issue":"10","key":"pone.0353564.ref027","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40618-019-01047-0","article-title":"Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis","volume":"42","author":"D Giugliano","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"pone.0353564.ref028","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11886-022-01706-4","article-title":"How much lowering of blood pressure is required to prevent cardiovascular disease in patients with and without previous cardiovascular disease?","volume":"24","author":"D Canoy","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"pone.0353564.ref029","doi-asserted-by":"crossref","first-page":"117236","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"LE Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"issue":"5","key":"pone.0353564.ref030","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/dc20-3007","article-title":"Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus White patients with and without type 2 diabetes","volume":"44","author":"MMY Lee","year":"2021","journal-title":"Diabetes Care"},{"issue":"10365","key":"pone.0353564.ref031","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"The Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"pone.0353564.ref032","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"D Cherney","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"pone.0353564.ref033","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14858","article-title":"Five comparative cohorts to assess the risk of genital tract infections associated with sodium\u2010glucose cotransporter\u20102 inhibitors initiation in type 2 diabetes mellitus","volume":"39","author":"W Alkabbani","year":"2022","journal-title":"Diabet Med"},{"issue":"7","key":"pone.0353564.ref034","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/DCR.0000000000000583","article-title":"Postdefecation cleansing methods: tissue paper or water? an analytical review","volume":"59","author":"P Garg","year":"2016","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"pone.0353564.ref035","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"MJ Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"pone.0353564.ref036","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update","volume":"29","author":"SL Samson","year":"2023","journal-title":"Endocr Pract"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:24:11Z","timestamp":1784309051000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353564"}},"subtitle":[],"editor":[{"given":"Alireza","family":"Shoari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353564","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}